Testing a new immune cell therapy for advanced blood cancer

Plain-English translation of NCT07802717 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a Phase 1 trial testing , an experimental therapy that works by reprogramming your own immune cells to recognize and attack myeloma cancer cells. The study will test different doses of this treatment to find the safest and most effective level, and then give the medication to additional patients at that optimal dose.

Multiple myeloma often comes back or stops responding to standard treatments, leaving patients with few options. This medication is designed to offer a new approach for people whose cancer is no longer controlled by approved therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with active multiple myeloma that has relapsed or stopped responding to treatment
you have already received at least 3 previous lines of cancer therapy, or you are not able to tolerate or are ineligible for standard approved treatments
you are at least 18 years old and in reasonably good health (ECOG performance status 0 or 1)
you have measurable disease that can be tracked by imaging or blood tests
you are willing and able to follow all study procedures and give informed consent

You likely don't qualify if…

you are pregnant, nursing, or unwilling to use reliable contraception during the study
you have an active HIV infection, as antiretroviral medications would interfere with how this treatment works
you have active myeloma involvement in your brain or central nervous system that has not been treated
you have had a major surgery within the last 28 days before enrollment
you have not fully recovered from the side effects of previous cancer treatments, except for mild stable nerve damage

What participation looks like

You would receive as an infusion—the study starts with lower doses in some patients and increases to higher doses as safety is confirmed. You will have regular clinic visits for blood work, imaging, and health checks to monitor how the treatment is working and any side effects. The trial involves close medical supervision, and you may need to stay in the hospital or visit the clinic frequently, especially early on, though the exact schedule will depend on which phase of the study you join and how you respond to the treatment.

AI-generated summary from trial data · Sep 19, 2026 · Not medical advice

Trial locations(1 site)

United States

The Mayo Clinic, Rochester, Minnesota